Bristol Myers Squibb (CELG-RI) Income from Non-Controlling Interests (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Income from Non-Controlling Interests of $1.0 million for Q1 2026, down 83.33% year-over-year from $6.0 million in Q1 2025, and up 200.0% quarter-over-quarter from -$1.0 million in Q4 2025.
Bristol Myers Squibb (CELG-RI) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Income from Non-Controlling Interests data on file, last reported at $1.0 million in Q1 2026.
- Income from Non-Controlling Interests for Q1 2026 came in at $1.0 million, down 83.33% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.0 million (down 122.22% YoY), and the FY2025 annual result was $2.0 million, down 86.67% from the prior year.
- Income from Non-Controlling Interests grew to $1.0 million in Q1 2026 per CELG-RI's latest filing, from -$1.0 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $8.0 million in Q2 2022 and troughed at -$6.0 million in Q3 2025.
- A 5-year average of $3.1 million and a median of $4.0 million in 2023 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2023 and 2025: Income from Non-Controlling Interests jumped 200.0% in 2023, then sank 250.0% in 2025.
- A 5-year view of Income from Non-Controlling Interests shows it stood at $3.0 million in 2022, then jumped by 100.0% to $6.0 million in 2023, then tumbled by 33.33% to $4.0 million in 2024, then slumped by 125.0% to -$1.0 million in 2025, then jumped by 200.0% to $1.0 million in 2026.
- Business Quant data shows CELG-RI's Income from Non-Controlling Interests at $1.0 million in Q1 2026, -$1.0 million in Q4 2025, and -$6.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.48 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 2.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -3.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 8.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 1.00 Mn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.00 Mn |
| Dec 31, 2025 | -1.00 Mn |
| Sep 30, 2025 | -6.00 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 6.00 Mn |
| Dec 31, 2024 | 4.00 Mn |
| Sep 30, 2024 | 4.00 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Mar 31, 2024 | 3.00 Mn |
| Sep 30, 2023 | 6.00 Mn |
| Jun 30, 2023 | 4.00 Mn |
| Mar 31, 2023 | 5.00 Mn |
| Dec 31, 2022 | 3.00 Mn |
| Sep 30, 2022 | 2.00 Mn |
| Jun 30, 2022 | 8.00 Mn |
| Mar 31, 2022 | 5.00 Mn |
| Sep 30, 2021 | 6.00 Mn |
| Jun 30, 2021 | 6.00 Mn |
| Mar 31, 2021 | 8.00 Mn |
| Sep 30, 2020 | 6.00 Mn |